These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 24438618)

  • 1. The percentage of peripheral blood blasts on day 7 of induction chemotherapy predicts response to therapy and survival in patients with acute myeloid leukemia.
    Gao S; Tan Y; Liu X; Su L; Yu P; Han W; Cui J; Li W
    Chin Med J (Engl); 2014; 127(2):290-3. PubMed ID: 24438618
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early clearance of peripheral blood blasts predicts response to induction chemotherapy in acute myeloid leukemia.
    Arellano M; Pakkala S; Langston A; Tighiouart M; Pan L; Chen Z; Heffner LT; Lonial S; Winton E; Khoury HJ
    Cancer; 2012 Nov; 118(21):5278-82. PubMed ID: 22517268
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Salvage by timed sequential chemotherapy in primary resistant acute myeloid leukemia: analysis of prognostic factors.
    Revesz D; Chelghoum Y; Le QH; Elhamri M; Michallet M; Thomas X
    Ann Hematol; 2003 Nov; 82(11):684-90. PubMed ID: 12928754
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Time to Clearance of Peripheral Blood Blasts Predicts Complete Remission and Survival in Chinese Adults with Acute Myeloid Leukemia.
    Li X; Zhu H; Zhang Y; Zhao W; Mi J; Hu J; Li J
    Acta Haematol; 2016; 135(4):217-23. PubMed ID: 26967450
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Treating patients with acute myeloid leukemias (AML) according to the protocol of the AML-01.10 Russian multicenter randomized trial: the coordinating center's results].
    Parovichnikova EN; Troitskaia VV; Kliasova GA; Kuz'mina LA; Sokolov AN; Paramonova EV; Galstian GM; Kessel'man SA; Drokov MIu; Vasil'eva VA; Obukhova TN; Kulikov SM; Savchenko VG
    Ter Arkh; 2014; 86(7):14-23. PubMed ID: 25314773
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical significance of day 5 peripheral blast clearance rate in the evaluation of early treatment response and prognosis of patients with acute myeloid leukemia.
    Yu C; Kong QL; Zhang YX; Weng XQ; Wu J; Sheng Y; Jiang CL; Zhu YM; Cao Q; Xiong SM; Li JM; Xi XD; Chen SJ; Chen B
    J Hematol Oncol; 2015 May; 8():48. PubMed ID: 25957890
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic impact of early response to induction therapy as assessed by multiparameter flow cytometry in acute myeloid leukemia.
    Kern W; Voskova D; Schoch C; Schnittger S; Hiddemann W; Haferlach T
    Haematologica; 2004 May; 89(5):528-40. PubMed ID: 15136215
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early blast clearance by remission induction therapy is a major independent prognostic factor for both achievement of complete remission and long-term outcome in acute myeloid leukemia: data from the German AML Cooperative Group (AMLCG) 1992 Trial.
    Kern W; Haferlach T; Schoch C; Loffler H; Gassmann W; Heinecke A; Sauerland MC; Berdel W; Buchner T; Hiddemann W
    Blood; 2003 Jan; 101(1):64-70. PubMed ID: 12393605
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of Peripheral Blast Clearance and Day 14 Bone Marrow Biopsy in Predicting Remission Status and Survival After 7+3 Induction in Acute Myeloid Leukemia.
    Covut F; Gupta D; Pinto R; Dambrosio N; El Jurdi N; Meyerson H; Ueda M; Kolk M; Creger R; Metheny L; Cooper BW; Caimi PF; Malek E; Otegbeye F; Lazarus HM; De Lima M; Tomlinson BK
    Clin Lymphoma Myeloma Leuk; 2019 Feb; 19(2):73-82. PubMed ID: 30528848
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [IDA-FLAG (idarubicin, fludarabine, high dosage cytarabine and G-CSF)--an effective therapy regimen in treatment of recurrent acute myelocytic leukemia in children and adolescents. Initial results of a pilot study].
    Fleischhack G; Graf N; Hasan C; Ackermann M; Breu H; Zernikow B; Bode U
    Klin Padiatr; 1996; 208(4):229-35. PubMed ID: 8926688
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early clearance of peripheral blasts measured by flow cytometry during the first week of AML induction therapy as a new independent prognostic factor: a GOELAMS study.
    Lacombe F; Arnoulet C; Maynadié M; Lippert E; Luquet I; Pigneux A; Vey N; Casasnovas O; Witz F; Béné MC
    Leukemia; 2009 Feb; 23(2):350-7. PubMed ID: 18987664
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [A new prognostic stratification for patients with acute myeloid leukemia].
    Jiang B; Mi YC; Lin D; Cai XJ; Fu MW; Li W; Wang Y; Liu XP; Xue YP; Bian SG; Wang JX
    Zhonghua Nei Ke Za Zhi; 2009 Apr; 48(4):316-20. PubMed ID: 19576124
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Addition of lomustine to idarubicin and cytarabine improves the outcome of elderly patients with de novo acute myeloid leukemia: a report from the GOELAMS.
    Pigneux A; Harousseau JL; Witz F; Sauvezie M; Bene MC; Luquet I; Hunault-Berger M; Recher C; Lioure B; Himberlin C; Escoffre-Barbe M; Berthou C; Lissandre S; Fegueux N; Cahn JY; Jourdan E; Dreyfus F; Reiffers J; Milpied N; Ifrah N
    J Clin Oncol; 2010 Jun; 28(18):3028-34. PubMed ID: 20479424
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oral Maintenance Chemotherapy with 6-Mercaptopurine and Methotrexate in Patients with Acute Myeloid Leukemia Ineligible for Transplantation.
    Choi YW; Jeong SH; Ahn MS; Lee HW; Kang SY; Choi JH; Park JS
    J Korean Med Sci; 2015 Oct; 30(10):1416-22. PubMed ID: 26425037
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pretreatment prognostic factors for overall survival in primary resistant acute myeloid leukemia.
    Colovic N; Tomin D; Vidovic A; Suvajdzic N; Jankovic G; Palibrk V; Djunic I; Djurasinovic V; Virijevic M
    Biomed Pharmacother; 2012 Dec; 66(8):578-82. PubMed ID: 23085253
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adding lomustine to idarubicin and cytarabine for induction chemotherapy in older patients with acute myeloid leukemia: the BGMT 95 trial results.
    Pigneux A; Perreau V; Jourdan E; Vey N; Dastugue N; Huguet F; Sotto JJ; Salmi LR; Ifrah N; Reiffers J
    Haematologica; 2007 Oct; 92(10):1327-34. PubMed ID: 18024370
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 6-Thioguanine, cytarabine, and daunorubicin (TAD) and high-dose cytarabine and mitoxantrone (HAM) for induction, TAD for consolidation, and either prolonged maintenance by reduced monthly TAD or TAD-HAM-TAD and one course of intensive consolidation by sequential HAM in adult patients at all ages with de novo acute myeloid leukemia (AML): a randomized trial of the German AML Cooperative Group.
    Büchner T; Hiddemann W; Berdel WE; Wörmann B; Schoch C; Fonatsch C; Löffler H; Haferlach T; Ludwig WD; Maschmeyer G; Staib P; Aul C; Gruneisen A; Lengfelder E; Frickhofen N; Kern W; Serve HL; Mesters RM; Sauerland MC; Heinecke A;
    J Clin Oncol; 2003 Dec; 21(24):4496-504. PubMed ID: 14673036
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IDA-FLAG regimen for the therapy of primary refractory and relapse acute leukemia: a single-center experience.
    Yavuz S; Paydas S; Disel U; Sahin B
    Am J Ther; 2006; 13(5):389-93. PubMed ID: 16988532
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Results of acute myeloid leukemia treatment. Analysis of 63 patients between 2010-2014].
    Fuentes M; Rojas P; Ernst D; Ocqueteau M; Bertin P; Sarmiento M; Ramírez P
    Rev Med Chil; 2015 Oct; 143(10):1269-76. PubMed ID: 26633270
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clearance of leukaemic blasts from peripheral blood during standard induction treatment predicts the bone marrow response in acute myeloid leukaemia: a pilot study.
    Gianfaldoni G; Mannelli F; Baccini M; Antonioli E; Leoni F; Bosi A
    Br J Haematol; 2006 Jul; 134(1):54-7. PubMed ID: 16803567
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.